{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:31:11Z","timestamp":1789601471426,"version":"build-2803163510"},"reference-count":18,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>A 51-year-old female presented to the emergency department with vertigo, visual disturbances, involuntary rapid repetitive eye movements, incoordination, and imbalance. Physical examination revealed opsoclonus, myoclonus, and bilateral limb and gait ataxia. Initial workup was negative for intracranial abnormalities, and no abnormalities were noted on blood work or cerebrospinal fluid analysis. Tumor markers were within normal limits. As part of her diagnostic workup, a positron emission tomography (PET) scan was performed, which showed a highly FDG-avid solitary 7 mm left axillary lymph node. Ultrasound-guided percutaneous biopsy revealed metastatic poorly differentiated carcinoma. Histopathological examination could not conclusively distinguish between adenocarcinoma and squamous cell carcinoma. She was diagnosed with seronegative opsoclonus-myoclonus ataxia syndrome of paraneoplastic origin from an occult primary malignancy and started on pulsatile corticosteroids and intravenous immunoglobulin (IVIG), with only moderate symptomatic improvement. Given the anatomic location and immunohistochemical staining pattern of the lymph node, the malignancy was considered as being of primary breast origin. A left axillary lymph node dissection was performed, with 1\/12 nodes testing positive for poorly differentiated carcinoma. The patient experienced significant improvement in her neurological symptoms 2\u20133 days following resection of the solitary malignant lymph node, largely regaining her functional independence. She went on to receive adjuvant radiotherapy to the breast and axilla, as well as adjuvant hormonal therapy.<\/jats:p>","DOI":"10.3390\/curroncol32080440","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T10:13:51Z","timestamp":1754475231000},"page":"440","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Seronegative Paraneoplastic Opsoclonus\u2013Myoclonus\u2013Ataxia Syndrome Secondary to Low Volume Endocrine-Sensitive Malignancy of Likely Breast Origin"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2745-6708","authenticated-orcid":false,"given":"Geraint","family":"Berger","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada"},{"name":"Department of Surgery, Division of General and Gastrointestinal Surgery, Dalhousie University, Halifax, NS B3H 2Y9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Jackson-Tarlton","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada"},{"name":"Department of Medicine, Division of Neurology, Dalhousie University, Halifax, NS B3H 3A7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rayson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada"},{"name":"Department of Medicine, Division of Medical Oncology, Dalhousie University, Halifax, NS B3H 2Y9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Silver","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada"},{"name":"Department of Medicine, Division of Neurology, Dalhousie University, Halifax, NS B3H 3A7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Walsh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada"},{"name":"Department of Surgery, Division of General and Gastrointestinal Surgery, Dalhousie University, Halifax, NS B3H 2Y9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Drohan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada"},{"name":"Department of Surgery, Division of General and Gastrointestinal Surgery, Dalhousie University, Halifax, NS B3H 2Y9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103676","DOI":"10.1016\/j.critrevonc.2022.103676","article-title":"Paraneoplastic syndromes review: The great forgotten ones","volume":"174","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: An approach to diagnosis and treatment","volume":"85","author":"Pelosof","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00108-017-0377-y","article-title":"Endocrine paraneoplastic syndromes","volume":"59","author":"Reisch","year":"2018","journal-title":"Der Internist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1756286420985323","DOI":"10.1177\/1756286420985323","article-title":"Paraneoplastic neurological syndromes: Clinical presentations and management","volume":"14","author":"Devine","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11060-018-03053-3","article-title":"Paraneoplastic neurological syndromes: A single institution 10-year case series","volume":"141","author":"Chan","year":"2019","journal-title":"J. Neuro-Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00415-018-9138-7","article-title":"Update on opsoclonus\u2013myoclonus syndrome in adults","volume":"266","author":"Oh","year":"2019","journal-title":"J. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/jamaneurol.2015.4607","article-title":"Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies","volume":"73","author":"Sabater","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00415-019-09544-1","article-title":"Epidemiology of paraneoplastic neurological syndromes: A population-based study","volume":"267","author":"Vogrig","year":"2020","journal-title":"J. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1474-4422(08)70060-7","article-title":"Paraneoplastic syndromes of the CNS","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/MOP.0b013e32833fde3f","article-title":"Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome","volume":"22","author":"Gorman","year":"2021","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12957-021-02436-7","article-title":"Breast cancer-associated opsoclonus-myoclonus syndrome: A case report","volume":"19","author":"Kostoglou","year":"2021","journal-title":"World J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2340\/00015555-3062","article-title":"Paraneoplastic Opsoclonus-Myoclonus Syndrome Preceding a Mucosal Malignant Melanoma","volume":"99","author":"Dresco","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1078155219831366","article-title":"Treatment-refractory paraneoplastic opsoclonus\u2013myoclonus syndrome in a patient with small-cell carcinoma of the lung","volume":"26","author":"Alkan","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ygyno.2010.01.017","article-title":"Paraneoplastic opsoclonus\u2013myoclonus syndrome secondary to immature ovarian teratoma","volume":"117","author":"Lou","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.mph.0000212991.64435.f0","article-title":"Rituximab (anti-CD20) Adjunctive Therapy for Opsoclonus-Myoclonus Syndrome","volume":"28","author":"Pranzatelli","year":"2006","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2352-4642(17)30130-X","article-title":"Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): A randomised, open-label, phase 3 trial","volume":"2","author":"Matthay","year":"2018","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e26819","DOI":"10.1002\/pbc.26819","article-title":"Therapeutic plasma exchange for a case of refractory opsoclonus myoclonus ataxia syndrome","volume":"65","author":"Greensher","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/archneurol.2012.1173","article-title":"Adult-Onset Opsoclonus-Myoclonus Syndrome","volume":"69","author":"Klaas","year":"2012","journal-title":"Arch. Neurol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/440\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:51:17Z","timestamp":1769507477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["curroncol32080440"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32080440","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}